Here’s to why Cara Therapeutics Inc. (CARA) stock rises during after-market?

Cara Therapeutics Inc. (NASDAQ: CARA) stock gained by 4.23% at last close while the CARA stock price surges by 26.05% in the after-hours trading session. Cara Therapeutics is a clinical-stage pharmaceutical business focusing on discovering and selling novel chemical entities that address peripheral kappa opioid receptors, or KORs, to relieve pruritus.

>> 7 Top Picks for the Post-Pandemic Economy << 

CARA stock Significant Development

KORSUVA (difelikefalin) for injection has been authorized by the US Food and Drug Administration to treat mild-to-severe pruritus linked with chronic kidney disease in people receiving hemodialysis, according to Cara Therapeutics. KORSUVA injectable is a first-in-class kappa opioid receptor (KOR) agonist for the peripheral nervous system. The FDA granted Priority Review to the KORSUVA injectable new drug application (NDA). It is contingent on the fact that, if authorized, the therapy will provide significant advances in the safety or efficacy of the treatment, diagnosis, or prevention of severe diseases when compared to existing treatments.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Read More

Positive findings from two key Phase 3 trials – KALM-1, conducted in the United States (New England Journal of Medicine 2020; 382:222-232), and the worldwide KALM-2 – as well as supporting data from an additional 32 clinical investigations, led to its clearance. The injection of KORSUVA was typically well-tolerated.


In the United States, Vifor Pharma and Cara have signed to an exclusive license to sell KORSUVA. In non-Fresenius Medical Care clinics in the United States, that deal includes a 60 percent Cara, 40 percent Vifor Pharma profit-sharing structure. Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics previously agreed to offer KORSUVA injectable to Fresenius Medical Care North America dialysis clinics in the United States under a Cara 50%, Vifor Pharma 50% profit-sharing deal.

>> 7 Top Picks for the Post-Pandemic Economy << 

To guarantee prompt reimbursement and patient access to KORSUVA injectable, Vifor Pharma and Cara Therapeutics are in the process of submitting the appropriate documents to the US Centers for Medicare and Medicaid Services. Vifor Pharma anticipates starting to promote KORSUVA Injection in Q1 2022, with reimbursement expected in H1 2022, depends on CMS timeline.

Related posts